Key Points
- Major shareholder James Peyer sold 25,000 shares of Sensei Biotherapeutics at an average price of $20.02, totaling about $500,500. After the sale, he still held 130,142 shares, reducing his ownership by 16.11%.
- Sensei Biotherapeutics reported a much worse-than-expected quarterly loss, posting EPS of ($131.45) versus the consensus estimate of ($0.62). Analysts expect the company to lose $2.77 per share for the full fiscal year.
- Wall Street sentiment is mixed but cautious, with a consensus rating of “Hold” and an average price target of $46.25. Recent analyst calls ranged from a sell downgrade to overweight and outperform ratings.
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Get Free Report) major shareholder James Peyer sold 25,000 shares of Sensei Biotherapeutics stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the transaction, the insider owned 130,142 shares of the company's stock, valued at $2,605,442.84. This represents a 16.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Sensei Biotherapeutics Price Performance
Shares of Sensei Biotherapeutics stock opened at $19.79 on Tuesday. Sensei Biotherapeutics, Inc. has a 1 year low of $5.60 and a 1 year high of $36.76. The company has a market capitalization of $26.52 million, a P/E ratio of -0.14 and a beta of -0.25. The business has a 50 day moving average price of $26.20 and a 200 day moving average price of $18.61.
Sensei Biotherapeutics (NASDAQ:SNSE - Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($130.83). As a group, research analysts expect that Sensei Biotherapeutics, Inc. will post -2.77 EPS for the current fiscal year.
Institutional Trading of Sensei Biotherapeutics
Several institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its stake in shares of Sensei Biotherapeutics by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company's stock valued at $123,000 after buying an additional 1,100 shares during the period. Bank of America Corp DE boosted its position in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock worth $1,041,000 after purchasing an additional 32,719 shares during the period. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics during the 1st quarter worth $4,188,000. Finally, Vivo Capital LLC purchased a new stake in Sensei Biotherapeutics during the 1st quarter worth $22,758,000. 10.50% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research analysts recently issued reports on SNSE shares. Wall Street Zen downgraded Sensei Biotherapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. Loop Capital set a $50.00 price objective on Sensei Biotherapeutics in a research report on Thursday. Leerink Partners assumed coverage on Sensei Biotherapeutics in a report on Monday, April 20th. They issued an "outperform" rating and a $50.00 price target for the company. Zacks Research upgraded Sensei Biotherapeutics to a "hold" rating in a report on Tuesday, April 21st. Finally, Cantor Fitzgerald assumed coverage on Sensei Biotherapeutics in a report on Friday. They issued an "overweight" rating for the company. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Sensei Biotherapeutics presently has a consensus rating of "Hold" and a consensus price target of $46.25.
Read Our Latest Stock Report on SNSE
About Sensei Biotherapeutics
(
Get Free Report)
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.
The company's lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
